Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ATHA
stocks logo

ATHA

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
AI Stock Picker
AI Stock Picker

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
--
--
-0.845
-78.33%
--
--
-1.900
-17.39%
--
--
-0.600
-66.67%
Estimates Revision
The market is revising No Change the revenue expectations for Athira Pharma, Inc. (ATHA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -0.20%.
EPS Estimates for FY2025
Revise Upward
up Image
+4.96%
In Past 3 Month
Stock Price
Go Down
down Image
-0.20%
In Past 3 Month
Wall Street analysts forecast ATHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATHA is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ATHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATHA is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
0 Buy
1 Hold
0 Sell
Hold
Current: 3.895
sliders
Low
4.00
Averages
4.00
High
4.00
Current: 3.895
sliders
Low
4.00
Averages
4.00
High
4.00
Mizuho
Graig Suvannavejh
Neutral
maintain
$5 -> $4
2025-09-19
Reason
Mizuho
Graig Suvannavejh
Price Target
$5 -> $4
2025-09-19
maintain
Neutral
Reason
Mizuho analyst Graig Suvannavejh lowered the firm's price target on Athira Pharma to $4 from $5 and keeps a Neutral rating on the shares following the 10-for-1 reverse stock split. The split has no impact on the company's underlying fundamentals, the analyst tells investors in a research note.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Athira Pharma Inc (ATHA.O) is -0.73, compared to its 5-year average forward P/E of -2.71. For a more detailed relative valuation and DCF analysis to assess Athira Pharma Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-2.71
Current PE
-0.73
Overvalued PE
1.09
Undervalued PE
-6.51

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-1.04
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
2.38
Undervalued EV/EBITDA
-4.47

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
0.00
Current PS
0.00
Overvalued PS
0.00
Undervalued PS
0.00
Financial AI Agent
Financial AI Agent

Financials

Annual
Quarterly
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Intellectia AI SwingMax
Intellectia AI SwingMax

ATHA News & Events

Events Timeline

(ET)
2025-09-11
09:08:36
Athira Pharma declares a 10-for-1 reverse stock split.
select
2025-08-14 (ET)
2025-08-14
07:20:25
Athira Pharma presents results from Phase 1 trial of ATH-1105 at ALS Nexus
select
2025-05-13 (ET)
2025-05-13
11:07:49
Athira Pharma to present data from first-in-human Phase 1 trial of ATH-1105
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
2.0
09-14TipRanks
Stock Splits Scheduled for This Week (September 15 to September 19) – Keep Your Investments Active

  • Upcoming Stock Splits: The week of September 15 to September 19 features several stock splits, including reverse splits from Clearside Biomedical, Sadot Group, Biodesix, VCI Global, and Next Technology Holding, aimed at maintaining Nasdaq listings and increasing share prices.

  • Stock Split Mechanics: A stock split increases the number of shares while lowering the price per share, making stocks more accessible to investors, whereas a reverse split consolidates shares to raise the price per share, often to comply with exchange listing requirements.

[object Object]
Preview
2.0
09-11Newsfilter
Athira Pharma Declares Reverse Stock Split

  • Reverse Stock Split Announcement: Athira Pharma, Inc. will implement a 10-for-1 reverse stock split effective September 17, 2025, to comply with Nasdaq's minimum bid price requirement and enhance the marketability of its common stock.

  • Impact on Shares: Following the split, every ten shares will convert into one, reducing the total authorized shares from 900 million to 90 million, while the par value remains unchanged at $0.0001. Adjustments will also be made to outstanding options and restricted stock units.

[object Object]
Preview
9.5
08-08NASDAQ.COM
Athira (ATHA) Q2 Loss Narrows 74%

  • Financial Performance: Athira Pharma reported a narrowed EPS loss of $(0.18) per share for Q2 2025, significantly improving from a $(0.70) loss in the previous year, while research and development costs dropped to $3.7 million due to a strategic focus on its lead candidate, ATH-1105.

  • Operational Focus and Future Needs: The company is concentrating on advancing ATH-1105 for ALS trials after halting its previous Alzheimer’s candidate, with cash reserves at $29.8 million highlighting an urgent need for partnerships or funding to support ongoing clinical development and operational expenses.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Athira Pharma Inc (ATHA) stock price today?

The current price of ATHA is 3.895 USD — it has increased 1.17 % in the last trading day.

arrow icon

What is Athira Pharma Inc (ATHA)'s business?

Athira Pharma, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecules to restore neuronal health and slow neurodegeneration. Its approach is designed to modulate the neurotrophic hepatocyte growth factor (HGF) system, which is critical to normal brain function. The Company’s lead drug candidate is ATH-1105. ATH-1105 is a novel, orally available, brain-penetrant small-molecule drug candidate designed to positively modulate the neurotrophic HGF system for the potential treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS), Alzheimer’s disease (AD), and Parkinson’s disease (PD). ATH-1105 is in development for the potential treatment of ALS. Its ATH-1020 is a novel, orally available small molecule drug candidate designed to positively modulate the neurotrophic HGF system. It has evaluated several other compounds in preclinical discovery and development for neurodegenerative diseases and other indications.

arrow icon

What is the price predicton of ATHA Stock?

Wall Street analysts forecast ATHA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ATHA is 4.00 USD with a low forecast of 4.00 USD and a high forecast of 4.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Athira Pharma Inc (ATHA)'s revenue for the last quarter?

Athira Pharma Inc revenue for the last quarter amounts to -6.87M USD, decreased -73.04 % YoY.

arrow icon

What is Athira Pharma Inc (ATHA)'s earnings per share (EPS) for the last quarter?

Athira Pharma Inc. EPS for the last quarter amounts to -4668000.00 USD, decreased -79.72 % YoY.

arrow icon

What changes have occurred in the market's expectations for Athira Pharma Inc (ATHA)'s fundamentals?

The market is revising No Change the revenue expectations for Athira Pharma, Inc. (ATHA) for FY2025, with the revenue forecasts being adjusted by % over the past three months. During the same period, the stock price has changed by -0.20%.
arrow icon

How many employees does Athira Pharma Inc (ATHA). have?

Athira Pharma Inc (ATHA) has 26 emplpoyees as of December 05 2025.

arrow icon

What is Athira Pharma Inc (ATHA) market cap?

Today ATHA has the market capitalization of 15.36M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free